Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2022-04-26 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
2021年度独立董事述职报告（袁自强）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021, authored by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on board matters, committee work, onsite investigations, investor protection efforts, and training. The content focuses on governance, oversight, and the director's role in corporate governance rather than financial results or audit opinions. It is not an annual report, audit report, or earnings release. It is a detailed report on the independent director's activities and governance role, which fits best under Board/Management Information (MANG) as it relates to management and board-level disclosures about governance and director duties. The document length is 1820 characters, which is short but contains substantive content about board activities, not just an announcement or certification. Therefore, the classification is MANG with high confidence.
2022-04-26 Chinese
2021年度独立董事述职报告（徐杰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021 by an independent director of the company. It details the director's attendance at board and shareholder meetings, opinions on company matters, committee work, communication with management, supervision of governance and disclosure, and training activities. It is a narrative report on the director's duties and activities rather than a financial report, audit, or regulatory filing. It does not contain financial statements or earnings data, nor is it an announcement or proxy solicitation. This type of document fits best under Board/Management Information (MANG) as it relates to management and board activities and disclosures about director duties and governance involvement.
2022-04-26 Chinese
2021年度独立董事述职报告（潘传云）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2021 for Zhuhai Sailong Pharmaceutical Co., Ltd. It details the independent director's attendance at board and shareholder meetings, opinions on various company matters, committee work, supervision of governance and disclosure, and training activities. The content is a detailed report on the independent director's duties and activities during the year, rather than an announcement or a brief summary. It is not a full annual report, audit report, or financial statement, but a management-related report focusing on governance and director duties. This fits best under Board/Management Information (MANG), which covers announcements related to board or senior management activities and reports. The document length is 2507 characters, which is relatively short but contains substantive content about the independent director's work, not just an announcement of a report. Therefore, the classification is MANG with high confidence.
2022-04-26 Chinese
西部证券股份有限公司关于赛隆药业集团股份有限公司2021年度募集资金存放与使用情况的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company (西部证券股份有限公司) acting as a sponsor, providing an audit opinion on the use and storage of funds raised by 赛隆药业集团股份有限公司 in their 2021 fiscal year. It includes detailed financial figures about the raised funds, their usage, storage, and compliance with regulatory requirements. The document references regulatory approvals, board meetings, shareholder meetings, and includes a detailed attachment with fund usage data. The content focuses on the verification and audit of the use of raised capital, not on the full annual financial performance or earnings. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory checks related to accounting and fund usage, excluding full annual reports. The document length (7731 characters) and detailed financial data support this classification rather than a brief announcement or a full annual report. Therefore, the filing type is AR with high confidence. FY 2021
2022-04-26 Chinese
营业收入扣除情况表专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (Special Verification Report) related to the company's 2021 fiscal year revenue deduction schedule. It is addressed to an accounting firm and includes detailed audit verification procedures and opinions on the revenue deduction schedule. The document references compliance with Shenzhen Stock Exchange listing rules and self-regulatory guidelines. It contains audit opinions and verification results but is not a full annual report or earnings release. The document is a standalone audit-related report focusing on a specific aspect of financial data (revenue deductions) and includes an auditor's verification opinion. The length is 2764 characters, which is relatively short but contains substantive audit content rather than just an announcement. Therefore, it fits best under Audit Report / Information (AR) category, which covers standalone audit reports and applied accounting principles excluding full annual reports. FY 2021
2022-04-26 Chinese
关于续聘公司2022年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the company's audit firm for the fiscal year 2022. It details the qualifications, independence, and experience of the audit firm, the approval process by the board and audit committee, and the need for shareholder approval. It does not contain any actual audit report, financial statements, or audit results. The document is relatively short (2902 characters) and serves as a formal announcement of the audit firm appointment rather than the audit report itself. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit-related announcements excluding full annual reports. FY 2022
2022-04-26 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.